Compare CNX & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CNX | MMED |
|---|---|---|
| Founded | 1860 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Medical/Dental Instruments |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 4.1B |
| IPO Year | 1998 | 2026 |
| Metric | CNX | MMED |
|---|---|---|
| Price | $31.99 | $15.29 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $35.71 | $22.56 |
| AVG Volume (30 Days) | ★ 2.0M | 1.1M |
| Earning Date | 04-30-2026 | 06-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 763.33 | N/A |
| EPS | ★ 2.18 | N/A |
| Revenue | ★ $2,239,134,000.00 | N/A |
| Revenue This Year | N/A | $15.99 |
| Revenue Next Year | $11.14 | $10.00 |
| P/E Ratio | $14.97 | ★ N/A |
| Revenue Growth | ★ 76.76 | N/A |
| 52 Week Low | $27.72 | $10.65 |
| 52 Week High | $43.62 | $17.86 |
| Indicator | CNX | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 32.73 | 57.03 |
| Support Level | $31.69 | $10.68 |
| Resistance Level | $33.98 | $15.74 |
| Average True Range (ATR) | 0.81 | 0.81 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 6.04 | 60.61 |
CNX Resources Corp is an independent natural gas development, production, midstream and technology company centered in the Appalachian Basin. It is focused on unconventional shale formations, prominently the Marcellus Shale and Utica Shale, in Pennsylvania, Ohio and West Virginia. Additionally, the company operates and develops Coalbed Methane (CBM) properties in Virginia. the company has two reportable segments: Shale and Coalbed Methane. The majority of the company's revenue is derived from the Shale segment.
Minimed Group Inc is a medical technology firm that develops, manufactures, and markets products and solutions for diabetes management. It offers automated insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens as its main products. The company sells these through direct-to-consumer channels and healthcare providers of various countries. The company's revenues are principally derived from the sale of reusable and single-use products which together comprise AID systems and smart multiple daily injection (MDI) systems for diabetes management to individuals, distributors, healthcare providers, and other institutions globally.